RxDoctor Payments Data

Philip Maple, MD

Internal Medicine · Fredericksburg, TXNPI 1386688810

Payments from drug & device makers

$1,195in general payments, 2019–2025

Across 79 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$446
  • GSK$183
  • Astellas Pharma US Inc$167
  • Johnson & Johnson$151
  • AbbVie$78
  • Amarin Pharma, Inc.$48
  • plus $122 from 8 others

What the payments were for

  • Food & beverage$1,12994%
  • Education$666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,195 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$153,405
Medicare patients
252
Services billed
3,567

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$56,864
TrulicityDulaglutide50$48,379
XareltoRivaroxaban35$32,027
JanuviaSitagliptin Phosphate31$25,817
MyrbetriqMirabegron44$22,418
MounjaroTirzepatide11$14,938
FarxigaDapagliflozin Propanediol18$14,914
NexlizetBempedoic Acid/Ezetimibe15$7,278
InvokanaCanagliflozin12$6,946
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,069
Breo ElliptaFluticasone/Vilanterol14$5,511
Levothyroxine Sodium284$4,509
Advair HfaFluticasone Propion/Salmeterol17$4,134
Ezetimibe143$3,112
Rosuvastatin Calcium219$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$11$63,31761 claims
Johnson & JohnsonXarelto, Invokana$151$38,97347 claims
MerckJanuvia$18$25,81731 claims
Astellas Pharma US IncMyrbetriq$167$22,41844 claims
AstraZenecaFarxiga$11$14,91418 claims
GSKBreo Ellipta$183$5,51114 claims
AbbVieSynthroid, Armour Thyroid$78$3,79263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fredericksburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →